High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: A phase I trial

Journal of Clinical Oncology

Volumn 15, Issue 4, 1997, Pages 1518-1528

  Tempero, M ^a   Leichner, P ^a   Dalrymple, G ^a   Harrison, K ^a   Augustine, S ^a   Schlam, J ^a   Anderson, J ^a   Wisecarver, J ^a   Colcher, D ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARMUSTINE; FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 2; IODINE 131; LEVAMISOLE; MITOMYCIN; MONOCLONAL ANTIBODY CC49; MONOCLONAL ANTIBODY CC49 I 131; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MEGADOSE; DRUG TOLERANCE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0030973970     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.4.1518     Document Type: Article

References (31)

1. Wingo PA, Tong Tm Bolden S: Cancer Statistics, 1995. CA Cancer Clin 45:8-30, 1995
2. Forastiere AA, Orringer MB, Perez-Tamayo C, et al: Concurrent chemotherapy and radiation therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus. J Clin Oncol 8:119-127, 1990
3. Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59:2006-2010, 1987
4. O'Connell MJ, Martenson JA, Wieand HS, et al: Improving adjuvant therapy for cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502-507, 1994
5. Doerr RJ, Herrera L, Abdel-Nabi H: In-111 CYT-103 monoclonal antibody imaging in patients with suspected recurrent colorectal cancer. Cancer 71:4241-4247, 1993
6. Colcher D, Horan Hand P, Nuti M, et al: A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 78:3199-3203, 1981
7. Johnson VG, Schlom J, Paterson AJ, et al: Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 46:850-857, 1986
8. Thor A, Ohuchi N, Szpak CA, et al: The distribution of oncofetal antigen TAG-72 defined by monoclonal antibody B72.3. Cancer Res 46:3118-3124, 1986
9. Muraro R, Kuroki D, Wunderlich D, et al: Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor associated glycoprotein 72 antigen. Cancer Res 48:4588-4596, 1988
10. Colcher D, Minelli MF, Roselli M, et al: Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res 48:4597-4603, 1988
11. Molinolo A, Simpsom JF, Thor A, et al: Enhanced tumor binding using immunohistochemical analyses by second generation antitumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. Cancer Res 50:1291-1298, 1990
12. 90Y-labeled anti-TAG-72 MAbs for the treatment of human colon carcinoma xenografts. Antibody Immunocon Radiopharm 4:31, 1990 (abstr)
13. Divgi CR, Scott AM, Dantis L, et al: Phase I radioimmunotherapy trial with Iodine-131-CC49 in metastatic colon cancer. J Nucl Med 36:586-592, 1995
14. 131I-CC49 in colorectal cancer. Cancer 73:1057-1066, 1994
15. Meredith RF, Bueschen AJ, Khazaeli MB, et al: Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 35:1017-1022, 1994
16. Hunter WM, Greenwood FC: Preparations of iodine-131 labelled human growth hormone of high specific activity. Nature 194:495-496, 1962
17. Colcher D, Milenic DE, Ferroni P, et al: In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J Nucl Med 31:1133-1142, 1990
18. Roselli M, Hitchcock CL, Molinolo A, et al: Autoradiographic evaluation of radiolabeled monoclonal antibody B72.3: Distribution in tumor and lymph nodes of adenocarcinoma patients. Anticancer Res 15:975-984, 1995
19. Hawkins WG, Leichner PK, Yang N-C: The circular harmonic transform for SPECT reconstruction and boundary conditions on the Fourier transform of the sinogram. IEEE Trans Med Images 7:135-148, 1988
20. Hawkins WG, Yang N-C, Leichner PK: Validation of the CHT algorithm for quantitative SPECT. J Nucl Med 32:141-150, 1991
21. Leichner PK, Vriesendorp HM, Hawkins WG, et al: Quantitative SPECT for In-111 labeled antibodies in the livers of beagle dogs. J Nucl Med 32:1442-1444, 1991
22. Leichner PK, Hawkins WG, Yang N-C: Quantitative SPECT imaging in radioimmunotherapy. Antibody Immunocon Radiopharm 4:25, 1990 (abstr)
23. Stabin M: MIRDOSE 3. Oak Ridge, TN, Radiation Internal Dose Information Center, Oak Ridge Institute for Science and Education, 1994
24. Sgouros G: Bone marrow dosimetry for radioimmunotherapy. J Nucl Med 34:689-694, 1993
25. Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219-1224, 1993
26. Press OW, Eary JF. Appelbaum FR, et al: A phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336-340, 1995
27. Gallinger S, Reilly RM, Kirsh JC, et al: Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients. Cancer Res 53:271-278, 1993
28. Greiner JW, Guadagni F, Goldstein D, et al: Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol 10:735-746, 1992
29. 131I-CC49) when given in combination with λ-interferon. Cancer Res 52:600-608, 1993
30. Murray JL, Macey DJ, Grant EJ, et al: Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following α-interferon treatment. Cancer Res 55:5925s-5928s, 1995 (suppl)
31. Berger MJ: Distribution of absorbed dose around point sources of electrons and beta particles in water and other media. MIRD Pamphlet No 7. New York, NY, Society of Nuclear Medicine, 1971, p 12